MA38714A1 - Procédés de production et formes cristallines d'un inhibiteur mdm2 - Google Patents

Procédés de production et formes cristallines d'un inhibiteur mdm2

Info

Publication number
MA38714A1
MA38714A1 MA38714A MA38714A MA38714A1 MA 38714 A1 MA38714 A1 MA 38714A1 MA 38714 A MA38714 A MA 38714A MA 38714 A MA38714 A MA 38714A MA 38714 A1 MA38714 A1 MA 38714A1
Authority
MA
Morocco
Prior art keywords
production processes
crystal forms
mdm2 inhibitor
intermediates
chlorophenyl
Prior art date
Application number
MA38714A
Other languages
English (en)
Inventor
Matthew Bio
Sebastien Caille
Brian Cochran
Yuanqing Fang
Brian M Fox
Brian S Lucas
Lawrence R Mcgee
Filisaty Vounatsos
Sean Wiedemann
Sarah Wortman
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51063849&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38714(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA38714A1 publication Critical patent/MA38714A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/25—Sulfonic acids having sulfo groups bound to carbon atoms of rings other than six-membered aromatic rings of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
    • C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
    • C07C309/35—Naphthalene sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C313/02—Sulfinic acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Epoxy Compounds (AREA)

Abstract

La présente invention concerne des procédés de production d'acide 2-((3r,5r,6s)-5-(3- chlorophényl)-6-(4-chlorophényl)-l-((s)-l-(isopropylsulfonyl)-3-méthylbutan-2-yl)-3- méthyl-2-oxopipéridin-3-yl)acétique ainsi que des intermédiaires et des procédés de production des intermédiaires. L'invention concerne également des formes cristallines du composé et les intermédiaires.
MA38714A 2013-06-10 2014-06-09 Procédés de production et formes cristallines d'un inhibiteur mdm2 MA38714A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361833196P 2013-06-10 2013-06-10
PCT/US2014/041594 WO2014200937A1 (fr) 2013-06-10 2014-06-09 Procédés de production et formes cristallines d'un inhibiteur mdm2

Publications (1)

Publication Number Publication Date
MA38714A1 true MA38714A1 (fr) 2017-10-31

Family

ID=51063849

Family Applications (3)

Application Number Title Priority Date Filing Date
MA38714A MA38714A1 (fr) 2013-06-10 2014-06-09 Procédés de production et formes cristallines d'un inhibiteur mdm2
MA53572A MA53572A1 (fr) 2013-06-10 2014-06-09 Procédés de production et formes cristallines d'un inhibiteur mdm2
MA43288A MA43288B1 (fr) 2013-06-10 2015-12-23 Procédés de production et formes cristallines d'un inhibiteur mdm2

Family Applications After (2)

Application Number Title Priority Date Filing Date
MA53572A MA53572A1 (fr) 2013-06-10 2014-06-09 Procédés de production et formes cristallines d'un inhibiteur mdm2
MA43288A MA43288B1 (fr) 2013-06-10 2015-12-23 Procédés de production et formes cristallines d'un inhibiteur mdm2

Country Status (37)

Country Link
US (10) US9376386B2 (fr)
EP (2) EP3008039B1 (fr)
JP (4) JP6998655B2 (fr)
KR (3) KR20230019216A (fr)
CN (3) CN105358530A (fr)
AP (1) AP2015008891A0 (fr)
AR (2) AR096582A1 (fr)
AU (4) AU2014278428B2 (fr)
BR (2) BR122020003153B1 (fr)
CA (4) CA3201958A1 (fr)
CL (3) CL2015003589A1 (fr)
CR (2) CR20210290A (fr)
CY (1) CY1123661T1 (fr)
DK (1) DK3008039T3 (fr)
EA (3) EA201891642A1 (fr)
ES (1) ES2851023T3 (fr)
HR (1) HRP20202065T1 (fr)
HU (1) HUE053047T2 (fr)
IL (4) IL297860A (fr)
JO (2) JOP20200296A1 (fr)
LT (1) LT3008039T (fr)
MA (3) MA38714A1 (fr)
MX (2) MX2015016856A (fr)
MY (1) MY194848A (fr)
NZ (1) NZ714821A (fr)
PE (2) PE20160113A1 (fr)
PH (1) PH12015502705A1 (fr)
PL (1) PL3008039T3 (fr)
PT (1) PT3008039T (fr)
RS (1) RS61192B1 (fr)
SG (2) SG10201801402XA (fr)
SI (1) SI3008039T1 (fr)
TN (1) TN2015000521A1 (fr)
TW (3) TWI649306B (fr)
UA (1) UA121301C2 (fr)
UY (1) UY35605A (fr)
WO (1) WO2014200937A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
EP2760845B1 (fr) 2011-09-27 2016-11-16 Amgen Inc. Heterocycles utilises comme inhibiteurs de mdm2 dans le traitement du cancer
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
JP6377123B2 (ja) 2013-03-14 2018-08-22 アムジエン・インコーポレーテツド 癌の治療のためのｍｄｍ２阻害剤としてのヘテロアリール酸モルホリノン化合物
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
BR112016010564A2 (pt) 2013-11-11 2017-10-10 Amgen Inc terapia de combinação incluindo um inibidor de mdm2 e um ou mais agentes farmaceuticamente ativos para tratamento de cânceres
WO2017201449A1 (fr) 2016-05-20 2017-11-23 Genentech, Inc. Conjugués anticorps-protac et procédés d'utilisation
PE20211653A1 (es) * 2018-04-30 2021-08-24 Kartos Therapeutics Inc Metodos para tratar cancer
AU2019273850A1 (en) * 2018-05-25 2021-01-07 Kartos Therapeutics, Inc. Methods of treating myeloproliferative neoplasms
CA3110525A1 (fr) * 2018-08-31 2020-03-05 Amgen, Inc. Procedes de preparation d'un inhibiteur de mdm2
CN110963958A (zh) * 2018-09-30 2020-04-07 上海长森药业有限公司 一种mdm2抑制剂，及其制备方法、药物组合物和应用
GB201919219D0 (en) 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
US20230272001A1 (en) * 2020-05-22 2023-08-31 Merck Sharp & Dohme Llc Novel processes for preparing conjugates of the il-2 protein
EP4204812A2 (fr) 2020-08-27 2023-07-05 Otsuka Pharmaceutical Co., Ltd. Biomarqueurs pour la thérapie anticancéreuse utilisant des antagonistes de mdm2
GB202103080D0 (en) 2021-03-04 2021-04-21 Otsuka Pharma Co Ltd Cancer biomarkers
WO2023014160A1 (fr) * 2021-08-05 2023-02-09 (주)바이오팜솔루션즈 Forme cristalline de phénylcarbamate et son procédé de préparation
WO2023039161A1 (fr) * 2021-09-09 2023-03-16 Kartos Therapeutics Procédés de traitement du cancer dépendant de l'expression du gène myc
WO2023056069A1 (fr) 2021-09-30 2023-04-06 Angiex, Inc. Conjugués agent de dégradation-anticorps et leurs procédés d'utilisation

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2483213A (en) * 1947-06-14 1949-09-27 American Cyanamid Co Alpha naphthalene sulfonic anhydride
GB1016828A (en) 1961-11-13 1966-01-12 Mcneilab Inc Substituted morpholines and process for preparing same
US3518236A (en) * 1967-07-20 1970-06-30 Uniroyal Inc Acceleration of sulfur-vulcanization of rubber with sulfinic acids and derivatives
DE3246148A1 (de) 1982-12-14 1984-06-14 Troponwerke GmbH & Co KG, 5000 Köln Pyrazolo(4.3-b)(1.4)oxazine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JP2604472B2 (ja) 1989-07-12 1997-04-30 株式会社クラレ 重合性組成物
WO1995023135A1 (fr) 1991-03-07 1995-08-31 Fisons Corporation Derives de diphenyl-2-piperidinone et -2-pyrrolidinone possedant une activite anticonvulsivante et neuroprotectrice
US5334720A (en) 1991-03-07 1994-08-02 Fisons Corporation Diphenyl-1-(aminoalkyl)-2-piperidinone and -2-pyrrolidinone derivatives having anticonvulsant properties
DK0776324T3 (da) 1994-08-19 2002-10-07 Abbott Lab Endothelin-antagonister
ATE323697T1 (de) 1996-02-13 2006-05-15 Abbott Lab Neue benzo-1,3-dioxolyl-und benzofuranyl substituierte pyrrolidinederivate als endothelin antagonisten
US6159990A (en) 1997-06-18 2000-12-12 Synaptic Pharmaceutical Corporation Oxazolidinones as α1A receptor antagonists
TR200501137T2 (tr) 1997-08-04 2005-12-21 Abbott Laboratories Endotelin antagonistleri.
WO1999031507A1 (fr) 1997-12-18 1999-06-24 Eli Lilly And Company Banques combinatoires sur la base de matrices peptidomimetiques
US6770658B2 (en) 1998-09-09 2004-08-03 Inflazyme Pharmaceuticals Ltd. Substituted γ-phenyl-Δ-lactams and uses related thereto
US7214540B2 (en) * 1999-04-06 2007-05-08 Uab Research Foundation Method for screening crystallization conditions in solution crystal growth
US6630006B2 (en) * 1999-06-18 2003-10-07 The Regents Of The University Of California Method for screening microcrystallizations for crystal formation
US7052545B2 (en) * 2001-04-06 2006-05-30 California Institute Of Technology High throughput screening of crystallization of materials
US7195670B2 (en) * 2000-06-27 2007-03-27 California Institute Of Technology High throughput screening of crystallization of materials
DE19951418A1 (de) * 1999-10-26 2001-05-03 Merck Patent Gmbh Verfahren zur Herstellung von N-(4,5-Bismethansulfonyl-2-methyl-benzoyl) -guanidin, Hydrochlorid
WO2002017912A1 (fr) 2000-08-31 2002-03-07 Abbott Laboratories Antagonistes de l'endotheline
AU2002228598A1 (en) * 2000-11-20 2002-06-03 Parallel Synthesis Technologies, Inc. Methods and devices for high throughput crystallization
EP1358178A2 (fr) 2001-01-30 2003-11-05 Bristol-Myers Squibb Company Lactames sulfonamide inhibiteurs de facteur xa (fxa) et technique
ATE409181T1 (de) 2001-05-08 2008-10-15 Univ Yale Proteomimetische verbindungen und verfahren
WO2002094787A1 (fr) 2001-05-23 2002-11-28 Ucb, S.A. Derives d'acide alcanoique 2-oxo-piperidinyl- et 2-oxo-azepanyle destines au traitement de l'epilepsie et d'autres troubles neurologiques
DE60225719T2 (de) 2001-12-18 2009-04-23 F. Hoffmann-La Roche Ag Cis-2,4,5- triphenyl-imidazoline und ihre verwendung bei der behandlung von tumoren
US6860940B2 (en) * 2002-02-11 2005-03-01 The Regents Of The University Of California Automated macromolecular crystallization screening
US6916833B2 (en) * 2003-03-13 2005-07-12 Hoffmann-La Roche Inc. Substituted piperidines
US7425638B2 (en) 2003-06-17 2008-09-16 Hoffmann-La Roche Inc. Cis-imidazolines
ES2314660T3 (es) 2004-05-18 2009-03-16 F. Hoffmann-La Roche Ag Nuevas cis-imidazolinas.
US7893278B2 (en) 2004-06-17 2011-02-22 Hoffman-La Roche Inc. CIS-imidazolines
JP2007297283A (ja) 2004-07-28 2007-11-15 Santen Pharmaceut Co Ltd 新規桂皮酸関連化合物
MX2007004551A (es) 2004-10-18 2007-05-23 Amgen Inc Compuestos tiadiazol y metodos de uso.
EP1854795B1 (fr) 2005-02-18 2016-06-01 Mitsubishi Tanabe Pharma Corporation Sel d'un dérivé de proline, solvate dudit sel, et méthode de production dudit sel
RU2411238C2 (ru) 2005-03-16 2011-02-10 Ф.Хоффманн-Ля Рош Аг Цис-2,4,5-триарилимидазолины и их применение в качестве противораковых лекарственных средств
JP5180816B2 (ja) 2005-04-04 2013-04-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 神経変性疾患および認知症のためのジヒドロピリジン化合物
CA2610838A1 (fr) 2005-06-07 2006-12-14 Ramot At Tel Aviv University Ltd. Nouveaux sels de medicaments psychotropes conjugues et leurs procedes de preparation
WO2007015929A2 (fr) 2005-07-27 2007-02-08 University Of Toledo Analogues d'epothilone
BRPI0619236A2 (pt) 2005-12-01 2011-09-20 Hoffmann La Roche derivados de 2,4,5-trifenil imidazolina, composição farmacêutica que os compreende, uso e processo para a sìntese dos mesmos
ES2389062T3 (es) 2006-01-18 2012-10-22 Amgen, Inc Compuestos de tiazol como inhibidores de proteína cinasa B (PKB)
US20070213341A1 (en) 2006-03-13 2007-09-13 Li Chen Spiroindolinone derivatives
AU2007269836A1 (en) 2006-06-30 2008-01-10 Albany Molecular Research, Inc. Substituted piperidines that increase P53 activity and the uses thereof
US7888375B2 (en) 2006-07-19 2011-02-15 The University Of Georgia Research Foundation, Inc Pyridinone diketo acids: inhibitors of HIV replication
US20080045560A1 (en) 2006-08-15 2008-02-21 Wyeth Pyrrolidine and related derivatives useful as PR modulators
US7618989B2 (en) 2006-08-15 2009-11-17 Wyeth Tricyclic oxazolidone derivatives useful as PR modulators
TW200831080A (en) 2006-12-15 2008-08-01 Irm Llc Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
GB0722769D0 (en) 2007-11-21 2008-01-02 Biolipox Ab New compounds
CA2680853C (fr) 2007-03-23 2012-07-17 Amgen Inc. Derives de quinoleine ou quinoxaline 3-substituee et leur utilisation en tant qu'inhibiteurs de phosphatidylinositol 3-kinase (pi3k)
WO2008118454A2 (fr) 2007-03-23 2008-10-02 Amgen Inc. Composés hétérocycliques et leurs utilisations
BRPI0809141A2 (pt) 2007-03-23 2014-08-26 Amgen Inc Composto, fabricação de um medicamento, e, composição farmacêutica
US7625895B2 (en) 2007-04-12 2009-12-01 Hoffmann-Le Roche Inc. Diphenyl-dihydro-imidazopyridinones
WO2008130614A2 (fr) 2007-04-20 2008-10-30 University Of Pittsburg-Of The Commonwealth System Of Higher Education Antagonistes p53/mdm2/mdm4 sélectifs et à action double
US7834179B2 (en) 2007-05-23 2010-11-16 Hoffmann-La Roche Inc. Spiroindolinone derivatives
WO2009004430A1 (fr) 2007-06-29 2009-01-08 Pfizer Inc. N-benzyl oxazolidinones et composés hétérocycliques apparentés comme potentialisateurs de récepteurs du glutamate
CN101809002B (zh) 2007-07-09 2013-03-27 阿斯利康(瑞典)有限公司 用于与mtor激酶和/或pi3k相关的疾病中的吗啉代嘧啶衍生物
EP2173728A2 (fr) 2007-07-17 2010-04-14 Amgen Inc. Modulateurs hétérocycliques de pkb
WO2009011871A2 (fr) 2007-07-17 2009-01-22 Amgen Inc. Thiadiazoles modulateurs de l'activité de pkb
WO2009017822A2 (fr) 2007-08-02 2009-02-05 Amgen Inc. Modulateur de la pi3 kinase et leurs procédés d'utilisation
AU2008309759A1 (en) 2007-10-09 2009-04-16 F. Hoffmann-La Roche Ag Chiral CIS-imidazolines
US7776875B2 (en) 2007-12-19 2010-08-17 Hoffman-La Roche Inc. Spiroindolinone derivatives
CL2008003798A1 (es) 2007-12-19 2009-10-09 Amgen Inc Compuestos derivados de heterobiciclos aromaticos sustituidos, inhibidores de pi3 quinasa; composicion farmaceutica; utiles en el tratamiento de cancer, melanomas, glioblastomas, entre otras enfermedades.
WO2009082038A2 (fr) 2007-12-26 2009-07-02 Eisai R & D Management Co., Ltd. Antagonistes des récepteurs ampa et zonisamide pour le traitement de l'épilepsie
AU2009225984A1 (en) 2008-03-21 2009-09-24 Chlorion Pharma, Inc. Substituted pyrrolidine and piperidine compounds, derivatives thereof, and methods for treating pain
US8415376B2 (en) 2008-05-30 2013-04-09 Amgen Inc. Inhibitors of PI3 kinase
GB0811643D0 (en) 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
WO2010030704A2 (fr) 2008-09-10 2010-03-18 Achaogen, Inc. Analogues d’aminoglycosides antibactériens
TW201011009A (en) 2008-09-15 2010-03-16 Priaxon Ag Novel pyrrolidin-2-ones
BRPI0919325A2 (pt) 2008-09-18 2021-03-30 F.Hoffmann-La Roche Ag Pirrolidina-2-carboxamidas substituídas
US20110263647A1 (en) 2009-01-15 2011-10-27 Amgen Inc. Fluoroisoquinoline substituted thiazole compounds and methods of use
EP2398791A1 (fr) 2009-02-18 2011-12-28 Amgen, Inc Composés d'indole ou benzimidazole convenant comme inhibiteurs de la kinase mtor
US8729074B2 (en) 2009-03-20 2014-05-20 Amgen Inc. Inhibitors of PI3 kinase
US8076482B2 (en) 2009-04-23 2011-12-13 Hoffmann-La Roche Inc. 3,3′-spiroindolinone derivatives
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
CA2760778A1 (fr) 2009-05-13 2010-11-18 Amgen Inc. Composes heteroaryle en tant qu'inhibiteurs des pikk
WO2010151735A2 (fr) 2009-06-25 2010-12-29 Amgen Inc. Composés hétérocycliques et leurs utilisations
BRPI1016150A2 (pt) 2009-06-25 2016-04-19 Amgen Inc compostos heterocíclicos e seus usos.
AU2010265971B2 (en) 2009-06-25 2014-08-14 Amgen Inc. Heterocyclic compounds and their uses as inhibitors of PI3 K activity
AU2010265932B2 (en) 2009-06-25 2014-11-20 Amgen Inc. Heterocyclic compounds and their uses
EA201200321A1 (ru) 2009-08-26 2012-09-28 Новартис Аг Тетразамещенные гетероарильные соединения и их применение в качестве модуляторов mdm2 и/или mdm4
CA2777107A1 (fr) 2009-10-09 2011-04-14 Achaogen, Inc. Analogues d'aminoglycoside antibacteriens
US8088815B2 (en) 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
JP2013519980A (ja) * 2010-02-10 2013-05-30 モチイ，インコーポレイテッド（ディービーエー ヴォクサ） 収差補正暗視野電子顕微鏡
IT1399923B1 (it) 2010-05-11 2013-05-09 Cbb Net S A Procedimento di preparazione di sali dell'acido (r) alfa-lipoico loro formulazione ed uso nelle composizioni farmaceutiche in forma di compresse che li contengono
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
CN103648499B (zh) 2011-01-10 2017-02-15 无限药品股份有限公司 用于制备异喹啉酮的方法及异喹啉酮的固体形式
CN102153557B (zh) 2011-01-21 2013-03-20 中国科学院上海有机化学研究所 具有乙二胺骨架的多手性中心氮杂环卡宾前体盐、合成方法及用途
JP6025713B2 (ja) * 2011-04-28 2016-11-16 大塚化学株式会社 アゾジカルボンアミドの新規製造法
TW201309651A (zh) 2011-06-29 2013-03-01 Otsuka Pharma Co Ltd 阿立哌唑（ａｒｉｐｉｐｒａｚｏｌｅ）無水物Ｂ形結晶微粒子之製造方法
EP2760845B1 (fr) 2011-09-27 2016-11-16 Amgen Inc. Heterocycles utilises comme inhibiteurs de mdm2 dans le traitement du cancer
CN103373951B (zh) * 2012-04-28 2016-03-09 上海医药工业研究院 一种拉帕替尼中间体的制备方法
AU2014219075C1 (en) 2013-02-19 2018-09-06 Amgen Inc. Cis-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
CA2902856C (fr) 2013-02-28 2021-02-16 Amgen Inc. Inhibiteur mdm2 derive de l'acide benzoique pour le traitement du cancer
JP6377123B2 (ja) 2013-03-14 2018-08-22 アムジエン・インコーポレーテツド 癌の治療のためのｍｄｍ２阻害剤としてのヘテロアリール酸モルホリノン化合物
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط

Also Published As

Publication number Publication date
EA201891642A1 (ru) 2019-08-30
RS61192B1 (sr) 2021-01-29
TW201536743A (zh) 2015-10-01
IL242622A0 (en) 2016-02-01
CN110627708A (zh) 2019-12-31
AR119727A2 (es) 2022-01-05
IL297860A (en) 2023-01-01
SG10201801402XA (en) 2018-04-27
JOP20200296A1 (ar) 2017-06-16
EA201592305A1 (ru) 2016-05-31
TWI698428B (zh) 2020-07-11
EP3008039B1 (fr) 2020-11-11
IL242622B (en) 2019-06-30
JP2020147573A (ja) 2020-09-17
JP2021130685A (ja) 2021-09-09
CA2914723C (fr) 2021-06-15
JP2016528179A (ja) 2016-09-15
US9855259B2 (en) 2018-01-02
JP2023089126A (ja) 2023-06-27
JP6891322B2 (ja) 2021-06-18
TW202035370A (zh) 2020-10-01
PE20160113A1 (es) 2016-03-03
US20160289178A1 (en) 2016-10-06
CA3200532A1 (fr) 2014-12-18
AP2015008891A0 (en) 2015-11-30
AU2022271425A1 (en) 2022-12-22
IL281807B2 (en) 2023-04-01
AU2020267169A1 (en) 2020-12-03
BR122020003153B1 (pt) 2022-09-27
EA202091612A1 (ru) 2020-10-05
EP3805232A1 (fr) 2021-04-14
PH12015502705B1 (en) 2016-03-14
SG11201509896VA (en) 2016-01-28
US9376386B2 (en) 2016-06-28
CA3115609C (fr) 2023-08-08
TN2015000521A1 (en) 2017-04-06
US9623018B2 (en) 2017-04-18
EA031254B1 (ru) 2018-12-28
US20140364455A1 (en) 2014-12-11
US20180092898A1 (en) 2018-04-05
NZ714821A (en) 2020-10-30
HRP20202065T1 (hr) 2021-02-19
DK3008039T3 (da) 2021-01-04
NZ753956A (en) 2020-12-18
KR20210121270A (ko) 2021-10-07
US9757367B2 (en) 2017-09-12
TWI649306B (zh) 2019-02-01
MA53572A1 (fr) 2021-10-29
AU2020267169B2 (en) 2022-08-25
ES2851023T3 (es) 2021-09-02
JP6998655B2 (ja) 2022-02-04
US20160289190A1 (en) 2016-10-06
IL281807A (en) 2021-05-31
BR112015031004B1 (pt) 2022-09-20
TW201922705A (zh) 2019-06-16
CR20210290A (es) 2021-07-23
JP7263439B2 (ja) 2023-04-24
PL3008039T3 (pl) 2021-04-19
CL2015003589A1 (es) 2016-06-17
AU2014278428B2 (en) 2018-11-15
US20160289243A1 (en) 2016-10-06
CL2021000566A1 (es) 2021-09-03
CN105358530A (zh) 2016-02-24
UA121301C2 (uk) 2020-05-12
TWI791153B (zh) 2023-02-01
UY35605A (es) 2015-01-30
CA3115609A1 (fr) 2014-12-18
IL266504A (en) 2019-07-31
MX2019012007A (es) 2019-11-11
KR20230019216A (ko) 2023-02-07
US9801867B2 (en) 2017-10-31
US20220280496A1 (en) 2022-09-08
AU2014278428A1 (en) 2015-11-26
AU2018260844B2 (en) 2020-08-13
AU2018260844A1 (en) 2018-11-22
IL281807B (en) 2022-12-01
MX2015016856A (es) 2016-04-07
US20230301974A1 (en) 2023-09-28
US20160287570A1 (en) 2016-10-06
CA3201958A1 (fr) 2014-12-18
US20200281912A1 (en) 2020-09-10
CR20160010A (es) 2016-02-04
MA43288B1 (fr) 2020-10-28
IL266504B (en) 2021-04-29
CA2914723A1 (fr) 2014-12-18
PH12015502705A1 (en) 2016-03-14
EP3008039A1 (fr) 2016-04-20
SI3008039T1 (sl) 2021-03-31
PE20210153A1 (es) 2021-01-26
LT3008039T (lt) 2021-01-25
MA43288A1 (fr) 2020-04-30
US20160264526A1 (en) 2016-09-15
CL2019000056A1 (es) 2019-05-03
MY194848A (en) 2022-12-19
JO3768B1 (ar) 2021-01-31
AR096582A1 (es) 2016-01-20
BR112015031004A2 (pt) 2020-05-12
CN110003092A (zh) 2019-07-12
CY1123661T1 (el) 2022-03-24
PT3008039T (pt) 2021-01-13
WO2014200937A1 (fr) 2014-12-18
HUE053047T2 (hu) 2021-06-28
KR20160018576A (ko) 2016-02-17

Similar Documents

Publication Publication Date Title
MA38714A1 (fr) Procédés de production et formes cristallines d'un inhibiteur mdm2
RS54030B1 (en) PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR CANCER TREATMENT
EA201590748A1 (ru) Противовирусные соединения против rsv
MA41607B1 (fr) Sels d'un inhibiteur de pi3k et procédés de préparation de ces sels
EA201691401A1 (ru) Индазольные соединения в качестве ингибиторов irak4
EA026892B9 (ru) ТРИАЗОЛОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ mPGES-1
EA201070912A1 (ru) Производные оксима в качестве ингибиторов hsp90
EA201001331A1 (ru) ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗ c-kit И PDGFR
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
EA201000149A1 (ru) Производные 1-фенил-2-пиридинилалкиловых спиртов в качестве ингибиторов фосфодиэстераз
TW200736247A (en) Compounds for the treatment of inflammatory disorders
BRPI0618381A2 (pt) processo para a preparação do hemi-sal de cálcio do ácido (3r, 5r) -7-[2-(4-fluorofenil) -5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico
EA201492170A1 (ru) Новые замещенные в цикле n-пиридиниламиды в качестве ингибиторов киназ
EA201001524A1 (ru) Ингибиторы дезацетилазы в, основанные на гидроксамате
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
EA200970940A1 (ru) Твердые формы (е)-1-(4-((1r,2s,3r)-1,2,3,4-тетрагидроксибутил)-1h-имидазол-2-ил)этаноноксима
EA201590942A1 (ru) Производные 1-[1-(бензоил)пирролидин-2-карбонил]пирролидин-2-карбонитрила
DK1926732T3 (da) Fremgangsmåde til fremstillingen af carbapenemforbindelser
EA202190632A1 (ru) Способы получения ингибитора mdm2
ATE509945T1 (de) Chirale mit phosphonsäureester- oder phosphonsäure- substituierte verbindungen
MX2016002763A (es) Formas cristalinas de un derivado de pirrolidona util en el tratamiento de la enfermedad de alzheimer y preparacion de las mismas.
IN2013MU02719A (fr)
CU23629A3 (es) Derivados sustituidos del pirrol